
    
      Name of Finished Product:

      Prolensa (Bromfenac Ophthalmic Solution) 0.07% Bausch and Lomb, Rochester, NJ Dose: Subjects
      will instill one drop into the study (operative) eye once daily for a maximum of 16 days.
      Dosing will begin one days prior to surgery (Day 1), continue on the day of surgery plus 1
      hour before surgery and for 14 days after surgery.

      2) IlevroÂ® (nepafenac ophthalmic suspension ) 0.3% This is a single-center, randomized,
      investigator and subject-masked, parallel group, and active-comparator controlled study.

      Subjects will be screened for this study between 1 and 21 days prior to the initiation of
      dosing with the test article. Subjects who sign the informed consent form and meet all
      inclusion/exclusion criteria will be randomized to receive either Prolensa (Bromfenac
      Ophthalmic Solution) 0.07% QD or Ilevro (nepafenac Ophthalmic Suspension) 0.3% (1:1) for 14
      days after cataract extraction.
    
  